BrightPath Biotherapeutics Co., Ltd. reported consolidated earnings results for the third quarter ended December 31, 2017. For the period, the company reported net sales of JPY 246 million against JPY 431 million a year ago. Operating loss was JPY 1,169 million against JPY 699 million a year ago. Ordinary loss was JPY 1,172 million against JPY 711 million a year ago. Loss attributable to owners of parent was JPY 1,175 million or JPY 31.52 per share against JPY 712 million or JPY 21.45 per share a year ago. Loss before income taxes was JPY 1,172.418 million against JPY 712.264 million a year ago.

For the year ending March 31, 2018, the company expects net sales of JPY 280 million, operating loss of JPY 2,000 million, ordinary loss of JPY 2,000 million and net loss of JPY 2,000 million or loss attributable to owners of parents of JPY 53.73 per share.